Teva Just Delivered More Good News on Its Biggest Growth Driver. Is the Stock Still a Bargain?
Teva has been building its comeback, and the latest studies on Austedo and Austedo XR will help further that momentum.
Teva Just Delivered More Good News on Its Biggest Growth Driver. Is the Stock Still a Bargain?
Overview
Teva Pharmaceuticals (NYSE: TEVA) is morphing from a generic drug maker into one that develops more innovative -- and profitable -- drugs. The stock is up more than 10% this year, and more than 95% over the past year.
On June 8, the company released data regarding its therapies, Austedo and Austedo XR (extended relief), at the Psych Congress Elevate. The three-year study showed that while more than 50% of tardive dyskinesia patients saw symptom improvement in controlling involuntary movements within 15 weeks, an additional 23% achieved success with long-term treatment.
This means that Austedo XR may be able to expand beyond its approved use to treat the involuntary movements (chorea) of Huntington's disease. The company also released a study on June 5 showing that 60% to 71% of Huntington's disease chorea patients experienced improvement with Austedo or Austedo XR.
Details
Source
Originally published at www.fool.com.
